These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29042336)

  • 1. Physicochemical properties of inclusion complexes of highly soluble β-cyclodextrins with highly hydrophobic testosterone propionate.
    Celia C; Scala A; Stancanelli R; Surdo E; Paolino D; Grattoni A; Micale N; Crupi V; Majolino D; Fresta M; Tommasini S; Venuti V; Ventura CA
    Int J Pharm; 2017 Dec; 534(1-2):316-324. PubMed ID: 29042336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Aqueous Solubility and Antihypercholesterolemic Activity of Ezetimibe on Formulating with Hydroxypropyl-β-Cyclodextrin and Hydrophilic Auxiliary Substances.
    Srivalli KM; Mishra B
    AAPS PharmSciTech; 2016 Apr; 17(2):272-83. PubMed ID: 26077622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of solubility and oral bioavailability of 2-(N-cyanoimino)-5-[(E)-4-styrylbenzylidene]-4-oxothiazolidine (FPFS-410) with antidiabetic and lipid-lowering activities in dogs by 2-hydroxypropyl-beta-cyclodextrin.
    Hara T; Hirayama F; Arima H; Yamaguchi Y; Uekama K
    Chem Pharm Bull (Tokyo); 2006 Mar; 54(3):344-9. PubMed ID: 16508189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solid-state 13C nuclear magnetic resonance spectroscopic study on amorphous solid complexes of tolbutamide with 2-hydroxypropyl-alpha- and -beta-cyclodextrins.
    Kimura K; Hirayama F; Arima H; Uekama K
    Pharm Res; 1999 Nov; 16(11):1729-34. PubMed ID: 10571279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether beta-cyclodextrin.
    Nagase Y; Hirata M; Wada K; Arima H; Hirayama F; Irie T; Kikuchi M; Uekama K
    Int J Pharm; 2001 Oct; 229(1-2):163-72. PubMed ID: 11604269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some pharmaceutical and inclusion properties of 2-hydroxybutyl-β-cyclodextrin derivative.
    Ishiguro T; Morishita E; Iohara D; Hirayama F; Wada K; Motoyama K; Arima H; Uekama K
    Int J Pharm; 2011 Oct; 419(1-2):161-9. PubMed ID: 21839823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue.
    Uekama K; Hieda Y; Hirayama F; Arima H; Sudoh M; Yagi A; Terashima H
    Pharm Res; 2001 Nov; 18(11):1578-85. PubMed ID: 11758766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the complexes of furosemide with 2-hydroxypropyl-beta-cyclodextrin and sulfobutyl ether-7-beta-cyclodextrin.
    Spamer E; Müller DG; Wessels PL; Venter JP
    Eur J Pharm Sci; 2002 Sep; 16(4-5):247-53. PubMed ID: 12208454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM; Elkheshen SA; Ghorab MM
    Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Water-soluble Complex of Curcumin with Cyclodextrins: Enhanced Physical Properties For Ocular Drug Delivery.
    Maria DN; Mishra SR; Wang L; Abd-Elgawad AH; Soliman OA; El-Dahan MS; Jablonski MM
    Curr Drug Deliv; 2017 Sep; 14(6):875-886. PubMed ID: 27501714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bicalutamide Anticancer Activity Enhancement by Formulation of Soluble Inclusion Complexes with Cyclodextrins.
    De Gaetano F; Cristiano MC; Paolino D; Celesti C; Iannazzo D; Pistarà V; Iraci N; Ventura CA
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36421730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state.
    Al Omari AA; Al Omari MM; Badwan AA; Al-Sou'od KA
    J Pharm Biomed Anal; 2011 Feb; 54(3):503-9. PubMed ID: 20971593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of some physicochemical properties of arundic acid, (R)-(-)-2-propyloctanonic acid, by complexation with hydrophilic cyclodextrins.
    Miyamoto Y; Nakahara M; Motoyama K; Ishiguro T; Oda Y; Yamanoi T; Okamoto I; Yagi A; Nishimura H; Hirayama F; Uekama K; Arima H
    Int J Pharm; 2011 Jul; 413(1-2):63-72. PubMed ID: 21540089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UV-vis and FTIR-ATR spectroscopic techniques to study the inclusion complexes of genistein with beta-cyclodextrins.
    Crupi V; Ficarra R; Guardo M; Majolino D; Stancanelli R; Venuti V
    J Pharm Biomed Anal; 2007 May; 44(1):110-7. PubMed ID: 17379467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution.
    Miyake K; Hirayama F; Uekama K
    J Pharm Sci; 1999 Jan; 88(1):39-45. PubMed ID: 9874700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel inclusion complex of ibuprofen tromethamine with cyclodextrins: physico-chemical characterization.
    Al Omari MM; Daraghmeh NH; El-Barghouthi MI; Zughul MB; Chowdhry BZ; Leharne SA; Badwan AA
    J Pharm Biomed Anal; 2009 Oct; 50(3):449-58. PubMed ID: 19545961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physicochemical and structural characterization of quercetin-beta-cyclodextrin complexes.
    Zheng Y; Haworth IS; Zuo Z; Chow MS; Chow AH
    J Pharm Sci; 2005 May; 94(5):1079-89. PubMed ID: 15793810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diloxanide furoate binary complexes with β-, methyl-β-, and hydroxypropyl-β-cyclodextrins: inclusion mode, characterization in solution and in solid state and in vitro dissolution studies.
    Aloisio C; Longhi M
    Pharm Dev Technol; 2018 Sep; 23(7):723-731. PubMed ID: 28758845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UV-vis and FTIR-ATR characterization of 9-fluorenon-2-carboxyester/(2-hydroxypropyl)-beta-cyclodextrin inclusion complex.
    Stancanelli R; Ficarra R; Cannavà C; Guardo M; Calabrò ML; Ficarra P; Ottanà R; Maccari R; Crupi V; Majolino D; Venuti V
    J Pharm Biomed Anal; 2008 Aug; 47(4-5):704-9. PubMed ID: 18400444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins.
    Mady FM; Farghaly Aly U
    Drug Des Devel Ther; 2017; 11():1681-1692. PubMed ID: 28652706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.